Ras al khaimah: Gulf Pharmaceutical Industries (Julphar) has released its financial results for the fiscal year ending December 31, 2025, showcasing impressive revenue growth and a substantial rise in profitability.
According to Emirates News Agency, the company reported a total revenue of AED1,075.5 million, marking an 8.4 percent growth in reported currency from continuing operations compared to the previous year. On a constant currency basis, this represents a 9.0 percent increase. The surge in profitability is highlighted by a net profit of AED173.3 million, which includes a one-time capital gain of AED111.2 million. This is a notable improvement from the prior year's net profit of AED44.9 million, which had a one-off capital gain of AED37.6 million.
Julphar's net operating profit from continuing operations stood at AED43.9 million, indicating an enhancement in core business performance. Furthermore, EBITDA from continuing operations rose by 22.2 percent year-on-year to AED109.4 million, a testament to the effective execution of strategic initiatives and sustained operational efficiency.
The company continues to maintain a robust financial position, with total assets amounting to AED1,779.8 million and shareholders' equity at AED959.8 million. This financial health underpins Julphar's growth trajectory and long-term strategic goals. Sheikh Saqer bin Humaid Al Qasimi, the Chairman of the Board, emphasized the company's strategic direction and commitment to creating lasting value beyond immediate results. He highlighted the importance of resilience, responsible growth, and sustainability in bolstering the company's position in evolving markets.
Basel Ziyadeh, Chief Executive Officer of Julphar, commented on the results, underscoring the company's progress in balancing investments, maintaining a solid capital structure, and creating sustainable long-term shareholder value. He credited the company's strong market position to the dedication and commitment of its teams across all operating regions.